PDCD1 and non-small cell lung carcinoma: Apart from melanoma, PD-1 inhibitors have also shown clinical efficacy in both solid and liquid cancers such as bladder, pancreatic, and non-small-cell lung cancer (NSCLC), follicular B cell, and non-Hodgkin lymphoma [45] (Table 2).